Evonik Chemicals Biz Steps
Up Pharma Polymers Research in India
Evonik Industries Chemicals Business Area expands laboratory space for
Pharma Polymers research, development and pharmaceuticals production in
Mumbai.
Essen, Germany-based Evonik Industries AG has vigorously expanded the
R&D center that it opened just five years ago in Mumbai, India. The
complex will also house the offices for the regional management of the
Group's 11 business units active on the Indian subcontinent, a region
that includes Bangladesh, Nepal, and Sri Lanka. "By making this move,
we're addressing the rapid growth of the Indian pharmaceuticals market,
from which our business has profited immensely in the past years,"
said Dr. Alfred Oberholz, member of Evonik Industries AG's Executive Board.
"With our innovation and know-how, we're well prepared to have a
share of this growth, both now and in the years to come."
India is a major cornerstone for Evonik's Pharma Polymers
The Mumbai R&D center, which also accommodates the technical service
and marketing departments of Pharma Polymers, a business line of the Specialty
Acrylics Business Unit, has in the last few years become one of the major
cornerstones of the global EUDRAGIT* polymers business. After the United
States, India ranks second worldwide in both the number of pharmaceutical
factories and the production of so-called generic drugs. Containing the
same active ingredient, a generic drug is a no-name imitation of a brand-name
drug that already exists on the market and whose patent has expired.
The Chemicals Business Area
of Evonik. Click
Here for High resolution image. photo: Evonik
Laboratory space for Pharma Polymers doubled
In its laboratory space, which has been enlarged from about 600 to 1,200
square meters, Pharma Polymers will develop EUDRAGIT formulations and
drug delivery technologies such as EUDRAMODE* for customers the world
over. EUDRAGIT, a neutral-tasting coating, ensures that the active ingredients
of drugs are released in the human body at the right place and at the
right time. This is made possible by specialty polymers, which function
as pharmaceutically neutral excipients and are used in the form of a white
powder, clear granules, or a milky liquid. So-called delayed-release medicines,
which release the active ingredient in a steady dose over several hours,
are becoming increasingly important. The drug is tolerated better because
it is released evenly, and instead of having to take the drug several
times a day, a patient need take only one tablet daily. To this end, Pharma
Polymers has developed EUDRAMODE, a technology platform with which pharmaceutical
companies can precisely adjust the release profile for a host of active
ingredients.
The enlarged laboratory's equipment includes fluidized bed coating units
and drum coaters, tablet presses and dryers, and analytical capabilities
for testing disintegration, resistance to breaking, hardness, and stability.
At its improved site, Pharma Polymers plans to support its customers in
the hot-melt extrusion segment, too, and to offer seminars and training.
Evonik Industries' Chemicals Business Area, as a technology leader in
specialty chemicals, has a total of 35 research and development centers
worldwide, among other places, in Tokyo, Japan; and Shanghai, China; as
well as in Piscataway, New Jersey, USA, and at several sites in Germany.
Certificate
In Strategic Leadership
Finance and Accounting for Nonfinancial Managers, Second Edition
CEU Credits: 2 (Choose 5 or 6 program courses for a total of 10
CEU's) Course Objective - Learn key financial concepts
and relate them to the financial management actions necessary for
the nonfinancial manager.
Get Started Today!
American
Management Online Training & Development Courses
Total
Quality Management
CEU Credits: 2 Course Objective Understand total quality
concept and techniques for managing, controlling, and improving
quality. Gain the information and skills needed to implement
total quality practices.
Sign Up for This Course Now!
All Rights Reserved. For permission to reproduce any contents of this
web site, please contact our Syndication department: Log onto HELP
